University of Adelaide Library

Adelaide Research and Scholarship : Schools and Disciplines : School of Medicine : Discipline of Medicine : Medicine Publications

Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/74262

Type: Journal article
Title: BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
Author: Branford, Susan
Yeung, David Tak On
Prime, Jodi
Choi, Soo-Young
Bang, Ju-hee
Park, Jin Eok
Kim, Dong-Wook
Ross, David Morrall
Hughes, Timothy Peter
Citation: Blood, 2012; 119(18):4264-4271
Publisher: American Society of Hematology
Issue Date: 2012
ISSN: 0006-4971
1528-0020
School/Discipline: Medicine
Statement of
Responsibility: 
Susan Branford, David T. Yeung, Jodi A. Prime, Soo-Young Choi, Ju-hee Bang, Jin Eok Park, Dong-Wook Kim, David M. Ross and Timothy P. Hughes
Abstract: Rising BCR-ABL1 transcripts indicate potential loss of imatinib response in CML. We determined whether the BCRABL1 doubling time could distinguish nonadherence from resistance as the cause of lost response. Distinct groups were examined: (1) acquired clinical resistance because of blast crisis and/or BCRABL1 mutations; and (2) documented imatinib discontinuation/interruption. Short doubling times occurred with blast crisis(median, 9.0 days; range, 6.1-17.6 days; n = 12 patients), relapse after imatinib discontinuation in complete molecular response (median, 9.0 days; range, 6.9-26.5 days; n = 17), and imatinib interruption during an entire measurement interval(median, 9.4 days; range, 4.2-17.6 days; n = 12; P = .72). Whereas these doubling times were consistently short and indicated rapid leukemic expansion, fold rises were highly variable: 71-, 9.5-, and 10.5- fold, respectively. The fold rise depended on the measurement interval, whereas the doubling time was independent of the interval. Longer doubling times occurred for patients with mutations who maintained chronic phase (CP: median, 48 days; range, 17.3-143 days; n = 29; P <.0001). Predicted short and long doubling times were validated on an independent cohort monitored elsewhere. The doubling time revealed major differences in kinetics according to clinical context. Long doubling times observed with mutations in CP allow time for intervention. A short doubling time for a patient in CP should raise the suspicion of nonadherence.
Rights: Copyright © 2012 by American Society of Hematology
RMID: 0020118975
DOI: 10.1182/blood-2011-11-393041
Appears in Collections:Medicine Publications
View citing articles in: Google Scholar
Scopus

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

© 2008 The University of Adelaide
library@adelaide.edu.au
CRICOS Provider Number 00123M
Service Charter | Copyright | Privacy | Disclaimer